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Abstract 
The start of chemotherapy treatment usually requires a delay of about 4 weeks after 
surgical resection in patients with primary colorectal cancer and synchronous distant 
metastasis. However, there is no evidence to indicate the required length of this delay 
interval. In addition, there is a chance that a patient may die because postoperative 
chemotherapy was not started soon enough and a metastatic tumor was able to develop 
rapidly. Here, we present a case in which combination chemotherapy with capecitabine 
and oxaliplatin (XELOX) was started within 1 week after a right hemicolectomy for 
synchronous multiple liver metastases. To our knowledge, this is the first report of the 
start of chemotherapy, involving treatments such as folinic acid, fluorouracil, and 
oxaliplatin (FOLFOX); folinic acid, fluorouracil, and irinotecan (FOLFIRI); and XELOX, 
within 1 week after a colorectal cancer operation with anastomosis. The findings suggest 
possible changes in the start time of chemotherapy after surgery in the future. 
 
Introduction 
The surgical resection of asymptomatic primary colorectal cancer with unresectable 
synchronous metastases is controversial. There is no doubt that, among patients with 
severe intestinal symptoms, resection is mandatory before starting systemic Case Rep Oncol 2011;4:250–254 
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chemotherapy [1–3]. Palliative resection of the primary tumor is also reported to improve 
the efficacy of systemic chemotherapy [4] and prolong the duration of chemotherapy [5]. 
A recent review article suggested that non-curative resection of asymptomatic colorectal 
primary tumors may prolong survival in patients with metastatic colorectal cancer [6]. On 
the other hand, another article concluded that initial chemotherapy should be started, 
with resection of the primary tumor reserved for the small proportion of patients who 
develop major complications from the primary tumor, because resection of an 
asymptomatic primary tumor provides only minimal palliative benefit [7]. 
The purpose of surgical resection of primary tumors is the prevention of hemorrhage, 
perforation, and bowel obstruction. In many cases, it is not possible for patients to 
continue chemotherapy treatments because of complications such as bleeding, 
perforation, and bowel obstruction after chemotherapy is started without surgical 
resection of the primary tumor. Thus, it seems necessary to surgically remove the primary 
tumor in order to continue chemotherapy with few complications. However, surgical 
resection may delay the start of chemotherapy [8]. Generally, an interval of 4 weeks is 
considered necessary after an operation before beginning chemotherapy treatments such 
as folinic acid, fluorouracil, and oxaliplatin (FOLFOX); folinic acid, fluorouracil, and 
irinotecan (FOLFIRI); and capecitabine and oxaliplatin (XELOX); however, there is no 
apparent evidence for this delay. A metastatic tumor can enlarge rapidly before the start 
of chemotherapy and possibly lead to patient death. Because the significance of the 
postoperative 4-week delay prior to the start of chemotherapy is not clear, we performed 
an early chemotherapy start in a patient who had undergone a right hemicolectomy for 
synchronous multiple liver metastases. 
Case Report 
A 43-year-old man was referred to our hospital with upper abdominal pain and abdominal fullness. 
Colonoscopy revealed a nearly obstructing tumor in the ascending colon. Stenosis prevented the 
endoscope from passing through. The patient needed to be fasted because of the stenosis of the 
ascending colon. Abdominal CT revealed more than 20 hepatic metastases (fig. 1a). The patient 
underwent a right hemicolectomy (open surgery) with functional end-to-end anastomosis. The oral side 
of the tumor was accompanied by significant edema and expansion of the ileum (fig. 2). No drain was 
used, and the nasogastric tube was removed immediately after surgery. After surgery, the patient was 
allowed to drink water. On postoperative day 1, the patient was offered a meal. The postoperative 
recovery was uneventful. The patient strongly hoped for an early start of chemotherapy on 
postoperative day 5. Therefore, we started XELOX therapy on postoperative day 7 [oxaliplatin (130 
mg/m
2) on day 1 plus capecitabine (1,000 mg/m
2) twice daily on days 1–14, every 3 weeks]. The patient 
was subsequently discharged in good condition on postoperative day 13. XELOX + bevacizumab [BV 
(7.5 mg/kg) and oxaliplatin (130 mg/m
2) on day 1 plus capecitabine (1,000 mg/m
2) twice daily on days 
1–14, every 3 weeks] was administered on postoperative day 28. After 6 cycles of XELOX + BV, CT 
revealed a reduction in tumor size (fig. 1b). Laboratory studies revealed a serum carcinoembryonic 
antigen level of 1,499 ng/ml, which improved to 312 ng/ml after 6 cycles of chemotherapy. Observed 
adverse events that had previously appeared included only a peripheral neuropathy in the acute stage 
(Grade 1) and hand-foot syndrome (Grade 1). Hematological toxicity, surgical site infection, and 
incisional hernia were not noted. 
Over the past 6 months, tumor progression has not occurred; the patient is now undergoing 
XELOX + BV therapy and works daily as a pharmacist. Case Rep Oncol 2011;4:250–254 
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Discussion 
The National Comprehensive Cancer Network currently recommends that patients 
with metastatic colorectal cancer undergo surgical intervention if they have bowel 
obstruction, an impending obstruction, or metastases that are potentially resectable. 
Complications from the primary lesion are uncommon in these circumstances, and the 
removal of the lesion delays initiation of systemic chemotherapy. Resection of colorectal 
cancer in patients with severe symptoms is mandatory before starting chemotherapy. In 
the past, some investigators recommended routine resection of the primary tumor in 
order to prevent the need for urgent surgical procedures because of local complications 
[1, 2]. In a study by Ruo et al. [9], 30 (29%) of the 103 patients who were initially managed 
without bowel resection required a subsequent operation for palliation of complications. 
Recently, some authors have suggested elective resection of asymptomatic colorectal 
cancers in at least a subset of patients with less advanced stage IV disease [3, 9]. Other 
authors have suggested deferring resection of minimally symptomatic colorectal tumors 
because most of these patients succumb to progressive systemic disease instead of the 
complications related to the intact primary lesion [8, 10, 11]. 
Currently, the precise timing for starting treatment with chemotherapeutic agents 
prior to and/or after surgery in order to avoid postoperative complications is not clear, 
but an at least 4-week interval has been suggested. In most clinical trials, patients who 
have undergone an operation within 4 weeks of the trial’s start are excluded. In Benoist et 
al.’s study, the mean interval between diagnosis and chemotherapy start was 44 days in 
the resection group versus 15 days in the chemotherapy group [8]. In this case, although 
an operation was performed, the interval between diagnosis and chemotherapy start was 
17 days. Resection of the primary tumor significantly increases hospital stay and delays 
the initiation of chemotherapy, although there is no evidence to suggest that this delay is 
associated with reduced response rates leading to curative resection or reduced survival. 
However, there is a chance that patients may die if they are not able to start chemotherapy 
because of the rapid postoperative progression of a metastatic tumor [12, 13]. 
Enhanced recovery after surgery (ERAS) protocols aim at reducing the surgical stress 
response and optimizing recovery to reduce the length of hospital stay [14]. All elements 
in ERAS have separately been shown to improve patient outcome. Because ERAS was 
developed, an early start of chemotherapy after surgery has been enabled. An early start of 
chemotherapy after surgery may prevent tumor growth. 
Resection of colorectal tumors with severe stenosis and bleeding is the first step in 
treatment in order to prevent the complications related to colorectal tumors. An early 
start of chemotherapy after surgery may be safe and improve the prognosis of colon 
cancer patients with synchronous metastases. Prospective studies are needed to confirm 
the effect and safety of an early start of chemotherapy after surgery. We have already 
started a new clinical trial to examine patients receiving an early start of chemotherapy. 
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Fig. 1. Abdominal CT. a Imaging before chemotherapy. Multiple liver metastases are visible on the CT 
scan. b Imaging after 8 cycles of chemotherapy. Partial response can be seen on the CT scan. 
 
 
 
Fig. 2. Resected colon specimen. The resected colon specimen revealed a tumor in the ascending colon. 
The oral side of the tumor was accompanied by significant edema. 
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